Wang Yun-xi, Sun Yu-e, Li Xiang-hong, Wang Zhan-bo, Liu Yuan-lin, Chen Liang-an, Zhang Gao-kui
Department of Thoracic Surgery, General Hospital of the Chinese People's Liberation Army, Beijing 100853, China.
Zhonghua Yi Xue Za Zhi. 2007 Jan 16;87(3):161-4.
To investigate the practicability of detecting the micrometastasis in lymph nodes of no-small-cell lung cancer (NSCLC) by means of reverse transcriptase-polymerase chain reaction (RT-PCR).
Regional lymph node samples were collected during operation from 25 patients with NSCLC randomly selected. The lymph node sample from each patient was divided into 2 groups: lymph nodes of hilum of lung and of mediastinum. Every lymph node was divided into two parts of the same size. One half part of the lymph node was examined by hematoxylin eosin (H&E) staining. If HE staining discovered metastasis, further examination was not needed. If HE staining failed to discover metastasis, then all the remaining lymph node samples of each patient were mixed together to undergo RT-PCR for cytokeratin 19 (CK(19)), a tissue marker of epithelium and epithelial tumors.
(1) 195 lymph nodes from 25 patients with NSCLC were examined by H&E staining. 30 lymph nodes in 9 patients showed gross nodal metastasis and none showed micrometastatic tumor cells. (2) Of the 39 groups of mixed regional lymph node samples which were diagnosed to be devoid of metastases by H&E staining, 11 groups were found to have positive reactions to CK(19) mRNA. (3) Six of the sixteen patients staged as PN(0) had hilum lymph nodal micrometastasis, while 5 of nine patients with stage PN(1) had mediastinal lymph nodal micrometastasis (chi(2) = 54.063, P = 0.0043).
(1) H&E staining can accurately detect gross nodal metastasis in the lymph nodes of the patients with NSCLC, but is unfit for detecting lymph nodal micrometastasis. (2) RT-PCR can facilitate the detection of occult micrometastatic tumor cells in the lymph nodes of NSCLC, and its assessment of nodal micrometastasis can provide a refinement of molecular stage for partial patients with stage I to II.
探讨应用逆转录聚合酶链反应(RT-PCR)检测非小细胞肺癌(NSCLC)淋巴结微转移的可行性。
随机选取25例NSCLC患者手术中区域淋巴结样本。每位患者的淋巴结样本分为2组:肺门淋巴结和纵隔淋巴结。每个淋巴结均分成大小相同的两部分。其中一半淋巴结进行苏木精-伊红(H&E)染色检查。若HE染色发现转移,则无需进一步检查。若HE染色未发现转移,则将每位患者剩余的所有淋巴结样本混合在一起,进行细胞角蛋白19(CK(19))的RT-PCR检测,CK(19)是上皮及上皮性肿瘤的组织标志物。
(1)25例NSCLC患者的195个淋巴结经H&E染色检查。9例患者的30个淋巴结显示有明显的淋巴结转移,无淋巴结微转移瘤细胞。(2)在39组经H&E染色诊断无转移的混合区域淋巴结样本中,11组对CK(19) mRNA呈阳性反应。(3)16例分期为PN(0)的患者中有6例存在肺门淋巴结微转移,而9例分期为PN(1)的患者中有5例存在纵隔淋巴结微转移(χ(2)=54.063,P = 0.0043)。
(1)H&E染色能准确检测NSCLC患者淋巴结的明显转移,但不适用于检测淋巴结微转移。(2)RT-PCR有助于检测NSCLC患者淋巴结中隐匿的微转移瘤细胞,其对淋巴结微转移的评估可为部分Ⅰ至Ⅱ期患者提供分子分期的细化。